Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
US FDA approves Johnson & Johnson's device for heart condition
The FDA approved Johnson & Johnson's Varipulse, a pulsed field ablation system for treating drug refractory paroxysmal atrial fibrillation, which uses small burns or freezes to disrupt irregular heartbeats.
Immunomodulators Global Business Analysis Report 2024-2030
The Immunomodulators market is projected to grow from $248M in 2023 to $364.7M by 2030, driven by rising autoimmune diseases, advancements in biologics, and personalized medicine. Immunomodulators are crucial for treating immune-mediated diseases, with technological advancements expanding treatment options. The market segments include immunosuppressants, immunostimulants, and biologics, with biologics leading growth. Key regions like the U.S. and China show significant growth potential.
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
Gilead Sciences reported 7% Q3 revenue growth, with $7.5B in earnings surpassing forecasts. The company raised its full-year product sales guidance to $27.8B-$28.1B and adjusted profit forecast to $4.25-$4.45 per share. HIV sales grew 9% to $5.1B, driven by Biktarvy's 13% surge to $3.5B. Gilead plans to file for FDA approval of twice-yearly subcutaneous PrEP lenacapavir by end of 2024, aiming to expand its reach. COVID-19 antiviral Veklury contributed $692M, while oncology drug Trodelvy missed estimates by $8M despite 17% growth. Gilead's CAR-T therapy anito-cel showed a 95% overall response rate in multiple myeloma patients.
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
The FDA approval of the Varipulse Platform, integrated with the Carto mapping system, allows electrophysiologists to perform accurate pulsed field ablation (PFA) procedures, potentially reducing procedure time and improving patient outcomes. The platform, previously under Biosense Webster, is now part of Johnson & Johnson MedTech, which aims to enhance its healthcare technology impact under a unified brand.
J&J wins FDA approval for Varipulse PFA system
Johnson & Johnson received FDA approval for its Varipulse pulsed field ablation system, joining Boston Scientific and Medtronic in the U.S. market for atrial fibrillation treatment. Varipulse is designed for drug-resistant, recurrent paroxysmal AFib and integrates with J&J's Carto 3 mapping system. The PFA technology is seen as safer and more efficient than older ablation methods.
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Rallybio reports Q3 2024 financials, $75.1M cash runway into mid-2026, and CTA approvals for RLYB212 Phase 2 trial, set to initiate screening in 4Q 2024.
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty reports Q3 2024 financials: $7.2M income, FDA approval for Zevra’s MIPLYFFA™ (arimoclomol), $15M royalty monetization with Twist Bioscience, $9.9M cash receipts in Q3, $42.3M YTD.
Drug giants display advanced technologies, solutions at CIIE
At the 7th China International Import Expo, Johnson & Johnson launched INVEGA HAFYERA for schizophrenia, Pfizer showcased dermatology solutions, and GSK announced Phase III studies for Bepirovirsen, a potential hepatitis B treatment, and a public welfare project for systemic lupus erythematosus.
Shockwave Medical Shares First Clinical Outcomes Associated With ...
Shockwave Medical announces first clinical outcomes for Shockwave Javelin Peripheral Intravascular Lithotripsy (IVL) Catheter, showing 99% technical acute procedural success rate. The non-balloon-based lithotripsy platform is designed for patients with peripheral artery disease (PAD). Results support FDA clearance, and the device is expected to have a limited market release soon.
© Copyright 2024. All Rights Reserved by MedPath